Skip to main content

Table 3 Perindopril and echocardiographic data

From: Perindopril treatment promote left ventricle remodeling in patients with heart failure screened positive for autoantibodies against angiotensin II type 1 receptor

 

(+) anti- AT1-AR (n = 82)

(−) anti- AT1-AR (n = 56)

Baseline

One-year

Baseline

One-year

LVEDD (mm)

69.5 ± 0.6

58.0 ± 0.8*†

69.9 ± 0.9

61.0 ± 0.6*

LVEDD (mm)

56.2 ± 0.6

42.0 ± 0.7*†

55.7 ± 0.8

47.1 ± 1.0*

LVEF (%)

34.1 ± 0.6

49.6 ± 1.2*†

33.8 ± 0.9

44.3 ± 1.1*

  1. LVEDD, left ventricular end-diastolic dimension; LVESD, left ventricular end-systolic dimension; LVEF, left ventricular ejection fraction.
  2. Both groups of patients showed significant improvement in response to perindopril therapy. Of note, the presence of (+) anti-AT1-AR group experienced more pronounced benefits than the (−) anti-AT1-AR group. Data were collected and analysed as described in the text. (*P < 0.01 vs. baseline and †P < 0.05 vs. (−) anti-AT1-AR).
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us